Metagenomi Therapeutics, Inc. (MGX) vs Veru Inc. (VERU)

Metagenomi Therapeutics, Inc. and Veru Inc. are both Biotechnology companies. Metagenomi Therapeutics, Inc. and Veru Inc. are of similar size ($43.4M and $42.8M). Veru Inc. grew revenue faster over the last twelve months: 42.1% against −59.8%. Veru Inc. has the higher net margin (0.00% vs −689.2%) and the lower return on invested capital (−464.0% vs 0.00%). Across the 16 metrics below, Veru Inc. leads on 9 and Metagenomi Therapeutics, Inc. on 7.

Valuation

Metric MGX VERU Biotechnology median
P/E n/m n/m 7.88
P/S 3.19 2.53 11.47
P/B 0.38 2.06 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.49 n/m 0.74
EV/Sales (3.47) 2.04 10.73
Earnings yield (216.52%) (22.86%) (28.84%)
Free cash flow yield (198.11%) (44.48%) (23.03%)

Profitability

Metric MGX VERU Biotechnology median
Gross margin 100.00% 33.17% 65.16%
Operating margin (741.58%) 0.00% 0.00%
Net margin (689.20%) 0.00% 0.00%
Free cash flow margin (632.67%) 0.00% 0.00%
Return on equity (60.61%) (62.25%) (57.72%)
Return on assets (41.91%) (42.29%) (49.22%)
Return on invested capital 0.00% (464.03%) 0.00%

Growth

Metric MGX VERU Biotechnology median
Revenue growth (TTM) (59.84%) 42.13% 5.64%
EPS growth (last fiscal year) 0.00% 44.64% —
Revenue growth, 5-year CAGR — (11.89%) 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric MGX VERU Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.50 4.42 4.73
Net debt to EBITDA 1.71 0.74 0.96

Dividend

Metric MGX VERU Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric MGX VERU Biotechnology median
Market cap 43.44m 42.80m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack